Teriflunomide Slows Brain Atrophy in Relapsing Multiple Sclerosis
Significant differences vs. placebo were maintained over 24 months.
ECTRIMS 2015
Rapid Assessment Tool Useful for Multiple Sclerosis Evaluation
The test can be completed in about one minute and is free to use for clinicians and researchers.
Expression of DICAM on TH17 Lymphocytes Documented in Neuroinflammation
DICAM was strongly linked with expression of ROR-γ, IL-23R, IL-17, IL-22, GM-CSF, and GZMB expression in human CD4+ lymphocytes.
NEDA-4 More Accurate Measure of Activity in Relapsing Multiple Sclerosis
The additional measure of brain volume loss results in a more comprehensive evaluation of disease activity in RRMS.
Comorbid MS, Major Depressive Disorder Linked to Brain Volume Loss
Changes to brain structure indicate possible underlying connection to idiopathic major depressive disorder.
Online Cognitive Behavioral Therapy Reduces Fatigue in Multiple Sclerosis
Participants also reported a reduction in anxiety and subjective cognitive impairment.
Smoking Cessation Slows Brain Volume Loss in Multiple Sclerosis
Compared to those who continued smoking, those who stopped experienced a significant decline in the rate of brain volume loss.
Grey, White Matter Ratio and Disability in Relapsing-Remitting Multiple Sclerosis
The ratio was also predictive of conversion to secondary-progressive MS.
Neurofilament Light Chain Level Predicts Brain Volume Loss at First Sign of MS
CSF NfL levels were predictive of brain volume loss at first sign of MS and follow-up.
Spinal Cord Grey Matter Atrophy Has Greatest Clinical Impact in MS
Spinal cord gray matter atrophy was found to be most relevant compared to other conventional MRI metrics.
Want to read more?
Please login or register first to view this content.
Next post in ECTRIMS 2015
